La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Voyager Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Voyager Therapeutics..

Voyager Therapeutics (NASDAQ:VYGR) Azioni, Catena delle Opzioni

VOYAGER THERAPEUTICS INC

Voyager Therapeutics

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics Inc

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

News

Legal

Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm

Health Care

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

General

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

Earnings

Voyager Reports First Quarter 2025 Financial and Operating Results

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

Voyager Reports Second Quarter 2025 Financial and Operating Results

Voyager to Present at Upcoming Investor Conferences

DAVE

PPTA

RCAT

VYGR

AC Immune

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Candel Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Crescent Biopharma

C4 Therapeutics

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Editas Medicine

Fennec Pharmaceuticals Inc. - Common Stock

Fennec Pharmaceuticals

Heron Therapeutics

Immutep Limited - American Depositary Shares

Immutep

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Invivyd

Jade Biosciences

Lyell Immunopharma

Neurogene

Puma Biotechnology

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics

Replimune Group

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Vanda Pharmaceuticals Inc. - Common Stock

Comments

Voyager Therapeutics

Voyager Therapeutics (VYGR) Opzioni

Voyager Therapeutics (NASDAQ:VYGR) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO